{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:47:30Z","timestamp":1786978050866,"version":"build-2736575974"},"reference-count":85,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":9934,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1984,11,12]]},"abstract":"<jats:p>During the past decade, the effectiveness of peripheral vasodilator drugs in the treatment of chronic occlusive arterial disease has been questioned. Pentoxifylline is a hemorheologic agent with primary actions that include increasing erythrocyte flexibility, reducing blood viscosity and increasing microcirculatory flow and tissue perfusion. The result is improved supply of oxygen to ischemic muscles of the limbs. In several double\u2010blind studies, pentoxifylline increased walking distance of patients with intermittent claudication in comparison to placebo or vasodilators. Like other methylxanthines, pentoxifylline is well absorbed in the gastrointestinal tract, almost completely metabolized in the body and excreted in the urine. The most significant difference in its pharmacokinetics is that, unlike other methylxanthines, it is bound to the erythrocytic membrane where it is initially metabolized. Although pentoxifylline has been shown to be effective in the treatment of intermittent claudication, additional research is needed to determine its use as adjunctive therapy in patients with concurrent coronary or cerebrovascular disease.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1984.tb03380.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T15:07:04Z","timestamp":1450278424000},"page":"297-306","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Pentoxifylline: A New Drug for the Treatment of Intermittent Claudication; Mechanism of Action, Pharmacokinetics, Clinical Efficacy and Adverse Effects"],"prefix":"10.1002","volume":"4","author":[{"given":"Domingo M.","family":"Aviado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"505","volume-title":"New antihypertensive drugs","author":"Aviado DM.","year":"1976"},{"key":"e_1_2_1_3_2","first-page":"13347","article-title":"Peripheral vasodilators for oral administration","volume":"36","author":"Food and Drug Administration.","year":"1971","journal-title":"Federal Register"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(59)91467-9"},{"key":"e_1_2_1_5_2","first-page":"169","article-title":"The treatment of intermittent claudication","volume":"21","author":"Hamilton M","year":"1952","journal-title":"Q J Med"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197903293001305"},{"key":"e_1_2_1_7_2","first-page":"43","volume-title":"Pharmacologic approach to treatment of limb ischemia","author":"Coffman JD.","year":"1983"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI100749"},{"key":"e_1_2_1_9_2","first-page":"1159","article-title":"Zuer Chemie und Synthese von 3,7\u2010Dimethyl\u20101\u2010(5\u2010oxo\u2010hexyl)\u2010xanthin","volume":"21","author":"Mohler W","year":"1971","journal-title":"(On chemistry and synthesis of 3.7-dimethyl-1-(5-oxo-hexyl)-xanthine.) Arzneimittelforsch"},{"key":"e_1_2_1_10_2","first-page":"1456","article-title":"Zur Analytik von 3,7\u2010Dimethyl\u20101\u2010(5\u2010oxo\u2010hexyl)\u2010xanthin. 1. Mitteilung: Zur Spektroskopie von 3.7\u2010dimethyl\u20101\u2010(5\u2010oxo\u2010hexyl)\u2010xanthin. (Analysis of 3,7\u2010dimethyl\u20101\u2010(5\u2010oxo\u2010hexyl)\u2010xanthine. 1","volume":"21","author":"Hinze HJ.","year":"1971","journal-title":"Spectroscopy of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine.) Arzneimittelforsch"},{"key":"e_1_2_1_11_2","first-page":"2045","article-title":"Zur Analytik von 3,7\u2010Dimethyl\u20101\u2010(5\u2010oxo\u2010hexyl)\u2010xanthin (BL 191). 2. Mitteilung: Zur Chromatographie und quantitativen Bestimmung von BL 191. (Analysis of 3,7\u2010Dimethyl\u20101\u2010(5\u2010oxo\u2010hexyl)\u2010xanthin. 2","volume":"21","author":"Hinze HJ.","year":"1971","journal-title":"Chromatography and quantitative estimation of BL 191.) Arzneimittelforsch"},{"key":"e_1_2_1_12_2","first-page":"1932","article-title":"Der Effekt von Pentoxifyllin, Xantinol\u2010nicotinat und Theophyllin auf das Kreislaufsystem, die myokariale Dynamik und die linksventricul\u00e4re Kontraktilit\u00e4t beim Hund im akuten Experiment","volume":"27","author":"Komarek J","year":"1977","journal-title":"(Acute effect of pentoxifylline, theophylline, and xanthinol nicotinate on the circulatory system, myocardial dynamics, and left ventricular contractility in dogs.) Arzneimittelforsch"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1975.29"},{"key":"e_1_2_1_14_2","first-page":"174","article-title":"The effect of 3,7\u2010dimethyl\u20101\u2010(5\u2032\u2010oxohexyl)\u2010xanthin on the \u03b2\u2010adrenergic receptors and on the activity of isoprenaline","volume":"194","author":"Boksay I","year":"1971","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.23.235"},{"key":"e_1_2_1_16_2","first-page":"385","article-title":"The effect of pentoxifylline on central and peripheral haemodynamics\u2014an experimental clinical study","volume":"65","author":"Heidrich H","year":"1976","journal-title":"Z Kardiol"},{"key":"e_1_2_1_17_2","first-page":"5872","article-title":"Erweiterte M\u00f6glichkeiten zur konservativen Behandlung arterieller Durchblutungst\u00f6rungen","volume":"27","author":"Baumann JC.","year":"1977","journal-title":"(Increase possibilities for conservative treatment of arterial circulatory distrubances.) Therapiewoche"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)92778-1"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331977602700306"},{"key":"e_1_2_1_20_2","first-page":"1567","article-title":"Influence of pentoxifylline (Trental) on platelet aggregation (Japanese)","volume":"19","author":"Kuzuya F.","year":"1977","journal-title":"Gendai no Shrinryo"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007997909109432"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007997709115279"},{"key":"e_1_2_1_23_2","first-page":"401","article-title":"Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication","volume":"10","author":"Ehrly AM.","year":"1982","journal-title":"IRCS Med Sci"},{"key":"e_1_2_1_24_2","first-page":"743","article-title":"Medikament\u00f6se Verbesserung der Flieseigenschaften des Blutes. Aine wirksames Prinzip zur Behandlung von arteriellen Durchblutungstorungen. (Improvement of the fluidity of the blood with medication","volume":"91","author":"Hess HV","year":"1973","journal-title":"An effective principle for the treatment of disturbances of the arterial blood flow.) Fortschr Med"},{"key":"e_1_2_1_25_2","first-page":"1244","article-title":"Behandlung von Arteriopathien mit Trental 400. Ergebnisse einer Doppelblidstudie","volume":"29","author":"V\u00f6lker D.","year":"1978","journal-title":"(Treatment of arteriopathies with Trental 400.) Med Welt"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00498562"},{"issue":"1","key":"e_1_2_1_27_2","first-page":"123","article-title":"The treatment of peripheral atherosclerosis with pentoxifylline","volume":"2","author":"Lusov VA","year":"1978","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_1_28_2","first-page":"229","article-title":"Changes in blood viscosity induced by pentoxifylline","volume":"1","author":"Smud R","year":"1976","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_1_29_2","volume-title":"Microcirculation","author":"Schmid\u2010Sch\u00f6nbein H.","year":"1977"},{"key":"e_1_2_1_30_2","first-page":"209","article-title":"Hemorrheology and peripheral vascular diseases. A new therapeutic approach","volume":"12","author":"M\u00fcller R.","year":"1981","journal-title":"J Med"},{"key":"e_1_2_1_31_2","first-page":"865","article-title":"Erfahrungen mit dem neuen Vasotherapeutikum Trental in der dermatologischen Fachpraxis","volume":"24","author":"Herger R.","year":"1972","journal-title":"(New vasotherapy with Trental in cutaneous ulcer.) Fortsch Med"},{"key":"e_1_2_1_32_2","first-page":"1593","article-title":"Zur Behandlung chronischer arterieller Angiopathien mit Pentoxifyllin (Trental)","volume":"67","author":"Mund\u2010Hoym WD.","year":"1978","journal-title":"(The treatment of chronic arterial blood circulatory interference.) Schweiz Rundschau Med"},{"key":"e_1_2_1_33_2","first-page":"563","article-title":"La pentossifillina nel trattamento delle arteriopatie obliteranti al secondo stadio (Pentoxifylline in the treatment of state II obliterative arteriopathy.)","volume":"35","author":"Brevetti G","year":"1979","journal-title":"Prog Med (Rome)"},{"key":"e_1_2_1_34_2","volume-title":"Doppler pressure measurements in multicenter study","author":"Hoechst\u2010Roussel Pharmaceuticals, Inc.","year":"1980"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(82)90401-X"},{"key":"e_1_2_1_36_2","first-page":"1093","article-title":"Behandlung von Patienten mit arterieller verschluskrankheit (Stadium II) mit Pentoxifylline. H\u00e4modynamische und ergometrische Befunde. (The influence of chronic pentoxifylline medication on ergometric and hemodynamic parameters in intermittent claudication.)","volume":"74","author":"Rudofsky G","year":"1979","journal-title":"Med Klin"},{"issue":"1","key":"e_1_2_1_37_2","first-page":"293","article-title":"Farmacologia clinica delle sostanze vasoattive: studi sulla pentoxifyllina. (Clinical pharmacology of a vasoactive substance: pentoxifylline.)","volume":"11","author":"Pupita F","year":"1981","journal-title":"Ric Clin Lab"},{"key":"e_1_2_1_38_2","first-page":"791","article-title":"Zur Behandlung der chronischen arteriellen Verschluskankheit. Klinische Studie mit einer neuen galenischem Zubereitung von Pentoxifyllin (Trental 400). (Treatment of chronic arterial occlusive disease. Clinical study with a new galenic preparation of pentoxifylline. Trental 400.)","volume":"73","author":"Angelkort B","year":"1978","journal-title":"Med Klin"},{"issue":"3","key":"e_1_2_1_39_2","first-page":"263","article-title":"Peripheral vasodilators versus pentoxifylline for the treatment of intermittent claudication","volume":"13","author":"Aviado DM.","year":"1983","journal-title":"Ric Clin Lab"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331978403500703"},{"key":"e_1_2_1_41_2","first-page":"359","article-title":"Observations upon muscular pain in intermittent claudication","volume":"15","author":"Lewis T","year":"1931","journal-title":"Heart"},{"key":"e_1_2_1_42_2","first-page":"55","article-title":"Peripheral vascular disorders","volume":"37","author":"Spittell JA","year":"1982","journal-title":"Geriatrics"},{"key":"e_1_2_1_43_2","first-page":"87","volume-title":"Pharmacologic approach to treatment of limb ischemia","author":"Spittell JA","year":"1983"},{"key":"e_1_2_1_44_2","first-page":"319","article-title":"Altered deformability of erythrocytes from patients with chronic occlusive arterial disease","volume":"5","author":"Ehrly AM","year":"1976","journal-title":"Vasa"},{"issue":"1","key":"e_1_2_1_45_2","first-page":"35","article-title":"Erythrocyte deformability in the pathophysiology of the microcirculation","volume":"11","author":"Dormandy JA","year":"1981","journal-title":"Ric Clin Lab"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1983.tb35214.x"},{"key":"e_1_2_1_47_2","first-page":"423","article-title":"Inhibicion de la fosfodiestererasa central y periferico y la pression arterial del perro","volume":"40","author":"Cicardo VH.","year":"1980","journal-title":"(Central and peripheral inhibition of phosphodiesterases and arterial blood pressure in the dog.) Medicina"},{"key":"e_1_2_1_48_2","first-page":"747","article-title":"Effect of pentoxifylline on energy\u2010rich rat's erythrocytes","volume":"10","author":"Steffanovich V.","year":"1975","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"e_1_2_1_49_2","first-page":"159","article-title":"Effects of pentoxifylline on membrane protein phosphorylation in rat erythrocytes","volume":"1","author":"Kramer JJ","year":"1983","journal-title":"Vasc Med"},{"key":"e_1_2_1_50_2","first-page":"1492","article-title":"Zur pharmakokinetic von 3,7\u2010Dimethyl\u20101\u2010(5\u2032\u2010oxo\u2010hexyl)\u2010xanthin (BL 191) am Menschen, (Pharmacokinetic of 3,7\u2010dimethyl\u20101\u2010(5\u2032\u2010oxo\u2010hexyl)\u2010xanthine (BL 191) in man.)","volume":"22","author":"Hinze HJ.","year":"1972","journal-title":"Arzneimittelforsch"},{"key":"e_1_2_1_51_2","first-page":"1144","article-title":"Strukt\u00fcr der Ausscheidungsprodukte des 3,7\u2010Dimethyl\u20101\u2010(5\u2032\u2010oxo\u2010hexyl)\u2010xanthin (BL 191) beim Menschen","volume":"22","author":"Hinze HJ","year":"1972","journal-title":"(Structure of metabolites of BL 191 in man.) Arzneimittelforsch"},{"key":"e_1_2_1_52_2","first-page":"160","article-title":"Bioavailability and pharmacokinetics of pentoxifylline from \u201cTrental 400\u201d in man","volume":"1","author":"Hinze HJ","year":"1976","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_1_53_2","volume-title":"Trental tablet dissolution","author":"Hoechst\u2010Roussel Pharmaceuticals, Inc.","year":"1982"},{"key":"e_1_2_1_54_2","volume-title":"Binding of pentoxifylline and metabolite M\u2010I to human erythrocytes. An in vitro study","author":"Hinze HJ","year":"1982"},{"key":"e_1_2_1_55_2","first-page":"1933","article-title":"Pharmakokinetische Untersuchungen nach oraler Verabreichung von 3,7\u2010Dimethyl\u20101\u2010(5\u2032\u2010oxohexyl)\u2010xanthin\u201014C (BL 191\u201014C) an Ratten, Hunde und Menschen","volume":"22","author":"Christ O","year":"1972","journal-title":"(Pharmacokinetic investigations after oral administration of 3,7-dimethyl-1-(5\u2032-oxo-hexyl)-xanthine-14C (BL 191)-14C) to rats, dogs and humans.) Arzneimittelforsch"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.3109\/03639048109057718"},{"key":"e_1_2_1_57_2","volume-title":"Allen\u2010Barker\u2010Hines' peripheral vascular diseases","author":"Juergens JL","year":"1980"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(82)90642-1"},{"key":"e_1_2_1_59_2","first-page":"1","volume-title":"Peripheral vascular diseases\u2014intermittent claudication study protocol. Draft guidelines from cardio\u2010renal section","author":"Food and Drug Administration.","year":"1976"},{"key":"e_1_2_1_60_2","first-page":"966","article-title":"Pharmacologic treatment of intermittent claudication","volume":"92","author":"Porter JM","year":"1982","journal-title":"Surgery"},{"key":"e_1_2_1_61_2","first-page":"264","article-title":"Trials of 3,7\u2010Dimethyl\u20101\u2010(5\u2032\u2010oxo\u2010hexyl)\u2010xanthine (BL 191) in double\u2010blind tests","volume":"31","author":"Buckert B","year":"1976","journal-title":"Farmaco (Prat)"},{"key":"e_1_2_1_62_2","first-page":"467","article-title":"Zur Behandlung von Durchblutungstorungen mit Pentoxifyllin. Eine Doppelblindstudie mit Trental. (Treatment of circulatory disturbances with pentoxifylline. Double\u2010blind trial with Trental.)","volume":"31","author":"Tonak J","year":"1977","journal-title":"Med Monatsschr Pharm"},{"key":"e_1_2_1_63_2","first-page":"557","article-title":"Double\u2010blind study of pentoxifylline against placebo in patients with intermittent claudication","volume":"1","author":"Bollinger A","year":"1977","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_1_64_2","first-page":"172","article-title":"Double\u2010blind trial of pentoxifylline in diabetics with peripheral vascular disorders","volume":"1","author":"Schubotz R.","year":"1976","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_1_65_2","first-page":"1399","article-title":"Zur Behandlung chronischer arterieller Diurchblutungstorungen. Doppelblindversuch mit Trental 400. (Treatment of chronic arterial circulatory disorders","volume":"118","author":"Kelllner H.","year":"1976","journal-title":"Double-blind trial with Trental 400.) M\u00fcnch Med Wochenschr"},{"key":"e_1_2_1_66_2","first-page":"35","article-title":"La pentoxifylline 400 dans le traitement de l'arterite obliterante. R\u00e9sultats pr\u00e9liminaires d'une \u00e9tude randomis\u00e9e et crois\u00e9e \u00e0 long terme versus Placebo. (Pentoxifylline 400 in the treatment of atherosclerosis obliterans","volume":"8","author":"Roekaerts F","year":"1982","journal-title":"Preliminary results in a randomized double-blind placebo-controlled study.) Actual Angeiologie"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331978303400105"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331978403500709"},{"key":"e_1_2_1_69_2","first-page":"48","article-title":"Zur objektivierung der therapeutischen Wirksamkeit von Trental 400. (Assessment of therapeutic efficiency of Trental 400; double\u2010blind trial in geriatric patients with vascular disorders.)","volume":"95","author":"Feine\u2010Haake G.","year":"1977","journal-title":"Fortschr Med"},{"key":"e_1_2_1_70_2","unstructured":"DonaldsonDR KesterRC RusselCW WigginsPA HallTJ Does oxpentifylline (Trental) have a place in the treatment of intermittent claudication?Third European conference on clinical pharmacology (London)1981;(abstract 164):82."},{"key":"e_1_2_1_71_2","first-page":"4941","article-title":"Behandlung arterieller und arterioven\u00f6ser Durchlutungsst\u00f6rungen mit Trental","volume":"25","author":"Mayer H","year":"1975","journal-title":"Therapiewoche"},{"key":"e_1_2_1_72_2","first-page":"370","article-title":"Influence of pentoxifylline (Trental 400) on microcirculation, poststenotic blood pressure and walking capacity in patients with chronic occlusive arterial disease","volume":"5","author":"Angelkort B.","year":"1977","journal-title":"IRCS Med Sci"},{"key":"e_1_2_1_73_2","first-page":"901","article-title":"Zur klinischen Erprobung von Trental 400 bei Gef\u00e4skranken mit peripherer arterieller Verschluskrankheit","volume":"119","author":"Westphalen JG.","year":"1977","journal-title":"(Clinical trial of Trental 400 in patients with peripheral arterial occlusive disease.) Munch Med Wochenschr"},{"key":"e_1_2_1_74_2","first-page":"1235","article-title":"Periphere Angiopathie\u2014Besteigerung der Mikrozirkulation. Argebnisse der ambulanten Behandlung in einer orthop\u00e4dischen Fachpraxis. (Peripheral angiopathy\u2014enhancement of the microcirculation","volume":"30","author":"Berke E","year":"1978","journal-title":"Results of ambulant treatment in an orthopedic consulting practice.) Arztl Prax"},{"key":"e_1_2_1_75_2","first-page":"1367","article-title":"Erfahrungen mit Pentoxifyllin bei charonischobliterierenden Erkrankungen der Beini\u2010arterien in Klinik und Praxis","volume":"30","author":"Sondern W","year":"1979","journal-title":"(Experiences with pentoxifylline in chronic obliterating diseases of the leg arteries in clinic and practice.) Med Welt"},{"key":"e_1_2_1_76_2","first-page":"1583","article-title":"Angioneuropathien, Angiopathien und andere Durchblutungstorungen Behandlung bein ambulanten Patienten. (Angioneuropathies, angiolopathies and other circulatory disorders","volume":"55","author":"Dembowski U","year":"1979","journal-title":"Treatment of outpatients.) Z Allg Med"},{"key":"e_1_2_1_77_2","first-page":"1019","article-title":"Pentoxifyllin\u2010Medikation im Rahmen der Ulcus cruris\u2010Behandlung. Ergebnisse einer Feldstudie mit Trental 400. (Pentoxifylline medication within the scope of leg\u2010ulcer therapy. Results of a field study using Trental 400.)","volume":"97","author":"Pemler K","year":"1979","journal-title":"Fortschr Med"},{"key":"e_1_2_1_78_2","first-page":"2638","article-title":"Durchblutungsf\u00f6rderung durch verbesserte mikrozirkulation","volume":"31","author":"Mattern H","year":"1979","journal-title":"(Enhanced blood circulation as a result of improved microcirculation.) Arztl Praxis"},{"key":"e_1_2_1_79_2","first-page":"1795","article-title":"Zur medikamentosen Behandlung von Arteiopathien. Studie mit Trental 400. (Drug therapy of arterial diseases","volume":"98","author":"Tannenberg G.","year":"1980","journal-title":"A study with Trental 400.) Fortschr Med"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331978403500701"},{"issue":"1","key":"e_1_2_1_81_2","first-page":"82","article-title":"Pentoxifylline in the treatment of peripheral vascular disease","volume":"2","author":"Komarov FI","year":"1978","journal-title":"Pharmatherapeutica"},{"issue":"1","key":"e_1_2_1_82_2","first-page":"66","article-title":"The clinical use of pentoxifylline","volume":"2","author":"Schindler H.","year":"1978","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_1_83_2","first-page":"1254","article-title":"Wirkung von pentoxifyllin auf die Leber\u2010durchblutung","volume":"74","author":"Koppenhagen K","year":"1979","journal-title":"(Effects of pentoxifylline in hepatic circulation.) Med Klin"},{"key":"e_1_2_1_84_2","first-page":"204","article-title":"Untersuchungen zur Pharmakokinetik von Pentoxifyllin bei chronischer Niereninsuffizienz. (Investigations on the pharmacokinetics of pentoxifylline in chronic renal failures.)","volume":"42","author":"Schaefer K","year":"1977","journal-title":"Med Klin"},{"key":"e_1_2_1_85_2","volume-title":"Chronic animal studies on Trental","author":"Hoechst\u2010Roussel Pharmaceuticals, Inc.","year":"1980"},{"key":"e_1_2_1_86_2","volume-title":"Trental. Physician's and package insert monograph","author":"Hoechst\u2010Roussel Pharmaceuticals, Inc.","year":"1984"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1984.tb03380.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1984.tb03380.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1984.tb03380.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:49:53Z","timestamp":1761061793000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1984.tb03380.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,11,12]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1984,11,12]]}},"alternative-id":["10.1002\/j.1875-9114.1984.tb03380.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1984.tb03380.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,11,12]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}